PTCT Ptc Therapeutics Inc

Price (delayed)

$36.2

Market cap

$2.56B

P/E Ratio

N/A

Dividend/share

N/A

EPS

-$5.59

Enterprise value

$2.91B

PTC is a science-driven, global biopharmaceutical company focused on the discovery, development and commercialization of clinically differentiated medicines that provide benefits to patients with rare disorders. PTC's ability to globally ...

Highlights
Ptc Therapeutics's revenue has soared by 52% YoY and by 10% from the previous quarter
PTCT's gross profit has soared by 51% YoY and by 10% QoQ
The quick ratio rose by 29% year-on-year but it has declined by 18% since the previous quarter
Ptc Therapeutics's equity has shrunk by 66% YoY and by 33% QoQ
The company's debt has surged by 57% YoY

Key stats

What are the main financial stats of PTCT
Market
Shares outstanding
70.6M
Market cap
$2.56B
Enterprise value
$2.91B
Valuations
Price to earnings (P/E)
N/A
Price to book (P/B)
12.97
Price to sales (P/S)
5.4
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
6.18
Earnings
Revenue
$471.89M
EBIT
-$268.15M
EBITDA
-$208.01M
Free cash flow
-$192.31M
Per share
EPS
-$5.59
Free cash flow per share
-$2.73
Book value per share
$2.79
Revenue per share
$6.7
TBVPS
$17.88
Balance sheet
Total assets
$2.06B
Total liabilities
$1.86B
Debt
$536.43M
Equity
$196.58M
Working capital
$775.27M
Liquidity
Debt to equity
2.73
Current ratio
3.66
Quick ratio
3.53
Net debt/EBITDA
-1.73
Margins
EBITDA margin
-44.1%
Gross margin
94.5%
Net margin
-82.9%
Operating margin
-70.5%
Efficiency
Return on assets
-18.3%
Return on equity
-105.5%
Return on invested capital
-20.5%
Return on capital employed
-15.2%
Return on sales
-56.8%
Dividend
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A

PTCT stock price

How has the Ptc Therapeutics stock price performed over time
Intraday
0.58%
1 week
-3.13%
1 month
-7.86%
1 year
-30.33%
YTD
-40.68%
QTD
-2.71%

Financial performance

How have Ptc Therapeutics's revenue and profit performed over time
Revenue
$471.89M
Gross profit
$445.87M
Operating income
-$332.65M
Net income
-$391.06M
Gross margin
94.5%
Net margin
-82.9%
Ptc Therapeutics's revenue has soared by 52% YoY and by 10% from the previous quarter
PTCT's gross profit has soared by 51% YoY and by 10% QoQ
PTCT's operating margin is up by 43% year-on-year and by 27% since the previous quarter
The company's net margin rose by 40% YoY and by 21% QoQ

Growth

What is Ptc Therapeutics's growth rate over time

Valuation

What is Ptc Therapeutics stock price valuation
P/E
N/A
P/B
12.97
P/S
5.4
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
6.18
The EPS is up by 19% year-on-year and by 16% since the previous quarter
PTCT's P/B is 116% above its 5-year quarterly average of 6.0 and 26% above its last 4 quarters average of 10.3
Ptc Therapeutics's equity has shrunk by 66% YoY and by 33% QoQ
Ptc Therapeutics's revenue has soared by 52% YoY and by 10% from the previous quarter
The price to sales (P/S) is 36% lower than the last 4 quarters average of 8.4 and 24% lower than the 5-year quarterly average of 7.1

Efficiency

How efficient is Ptc Therapeutics business performance
The ROIC has soared by 68% YoY and by 33% from the previous quarter
The ROS has soared by 56% year-on-year and by 30% since the previous quarter
The return on equity has declined by 44% year-on-year and by 8% since the previous quarter
Ptc Therapeutics's ROA has increased by 33% YoY and by 20% from the previous quarter

Dividends

What is PTCT's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A

There are no recent dividends present for PTCT.

Financial health

How did Ptc Therapeutics financials performed over time
The total assets is 11% more than the total liabilities
PTCT's total liabilities has surged by 106% year-on-year and by 2.3% since the previous quarter
The total assets has grown by 39% YoY but it has contracted by 2.5% from the previous quarter
The company's debt is 173% higher than its equity
Ptc Therapeutics's equity has shrunk by 66% YoY and by 33% QoQ
The company's debt has surged by 57% YoY

All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.